RT Journal Article
SR Electronic
T1 Outcomes in patients with ischemic stroke and newly diagnosed atrial fibrillation after stroke
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.01.23297948
DO 10.1101/2023.11.01.23297948
A1 Chang, Yu-Kang
A1 Hsu, Chih-Cheng
A1 Huang, Chi-Ting
A1 Lien, Chi-Hsun
A1 Hsu, Hung-Yi
YR 2023
UL http://medrxiv.org/content/early/2023/11/02/2023.11.01.23297948.abstract
AB BACKGROUND The clinical characteristics and long-term outcomes of patients with ischemic stroke (IS) and newly diagnosed atrial fibrillation after stroke (NAF) have not been clearly established. Previous studies evaluating patients with NAF were limited by the low prescription rates of anticoagulants and short follow-up periods.METHODS Consecutive patients hospitalized for IS between 2014 and 2017 were identified from a National Health Insurance Research Database. The included patients were categorized into three groups: (1) known diagnosis of AF (KAF) before the index stroke, (2) NAF, and (3) without AF (non-AF). Univariable and multivariable Cox regression analyses were performed to estimate the hazard ratio (HR) for independent variables and recurrent IS, hemorrhagic stroke, or death.RESULTS We identified 158,909 patients with IS of whom 16,699 (10.5%) had KAF and 7,826 (4.9%) had NAF. The patients with NAF were younger, more often male, and had lower CHA2DS2-VASc scores (3.8 ± 1.9 versus 4.9 ± 1.8, p < 0.001) than the patients with KAF. Anticoagulant treatment significantly reduced the risks of all outcomes. Compared with NAF, KAF was associated with lower risks of recurrent IS [hazard ratio (HR): 0.91, 95% confidence interval (CI): 0.86–0.97, p < 0.01] and hemorrhagic stroke (HR: 0.88, 95% CI: 0.79–0.99, p < 0.01) and a higher risk of all-cause mortality (HR: 1.11, 95% CI: 1.07–1.16, p < 0.001). The risks of all three outcomes were significantly higher for both NAF and KAF than for non-AF.CONCLUSIONS The risks of recurrent IS and hemorrhagic stroke were higher and of all-cause mortality was lower for patients with NAF than with KAF. Anticoagulant therapy significantly reduced the risks of recurrent IS, hemorrhagic stroke, and all-cause mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from Tungs' Taichung Metroharbor Hospital (protocol number TTMHH-109R0005).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical committee of Tungs' Taichung MetroHarbor Hospital in Taichung, Taiwan (protocol number 108077) and written informed consent was received from all patients.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available from the National Health Insurance Research Database (NHIRD) published by Taiwan National Health Insurance (NHI) Bureau. Due to legal restrictions imposed by the government of Taiwan in relation to the 'Personal Information Protection Act', data cannot be made publicly available. Requests for data can be sent as a formal proposal to the NHIRD (https://www.apre.mohw.gov.tw/#U).